279 related articles for article (PubMed ID: 37947611)
21. Efficacy of Hedgehog pathway inhibitors in Basal cell carcinoma.
Basset-Seguin N; Sharpe HJ; de Sauvage FJ
Mol Cancer Ther; 2015 Mar; 14(3):633-41. PubMed ID: 25585509
[TBL] [Abstract][Full Text] [Related]
22. A Vismodegib Experience in Elderly Patients with Basal Cell Carcinoma: Case Reports and Review of the Literature.
Passarelli A; Galdo G; Aieta M; Fabrizio T; Villonio A; Conca R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33202689
[TBL] [Abstract][Full Text] [Related]
23. Vismodegib for the treatment of basal cell carcinoma: results and implications of the ERIVANCE BCC trial.
Dessinioti C; Plaka M; Stratigos AJ
Future Oncol; 2014 May; 10(6):927-36. PubMed ID: 24941979
[TBL] [Abstract][Full Text] [Related]
24. The Hedgehog pathway and its inhibitors: Emerging therapeutic approaches for basal cell carcinoma.
Jain R; Dubey SK; Singhvi G
Drug Discov Today; 2022 Apr; 27(4):1176-1183. PubMed ID: 34896624
[TBL] [Abstract][Full Text] [Related]
25. Targeting the hedgehog pathway to treat basal cell carcinoma.
Geeraert P; Williams JS; Brownell I
J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
[TBL] [Abstract][Full Text] [Related]
26. Hedgehog Pathway Inhibition for the Treatment of Basal Cell Carcinoma.
Gutzmer R; Solomon JA
Target Oncol; 2019 Jun; 14(3):253-267. PubMed ID: 31243642
[TBL] [Abstract][Full Text] [Related]
27. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
[TBL] [Abstract][Full Text] [Related]
28. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway.
Sekulic A; Mangold AR; Northfelt DW; LoRusso PM
Curr Opin Oncol; 2013 May; 25(3):218-23. PubMed ID: 23493193
[TBL] [Abstract][Full Text] [Related]
29. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma.
Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR
J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394
[TBL] [Abstract][Full Text] [Related]
30. Molecular testing in metastatic basal cell carcinoma.
Verkouteren BJA; Wakkee M; van Geel M; van Doorn R; Winnepenninckx VJ; Korpershoek E; Mooyaart AL; Reyners AKL; Terra JB; Aarts MJB; Reinders MGHC; Mosterd K
J Am Acad Dermatol; 2021 Nov; 85(5):1135-1142. PubMed ID: 31870915
[TBL] [Abstract][Full Text] [Related]
31. Metastatic Basal Cell Carcinoma of the Skin: A Comprehensive Literature Review, Including Advances in Molecular Therapeutics.
Bisceglia M; Panniello G; Galliani CA; Centola M; D'Errico MM; Minenna E; Tucci FA; Ben-Dor DJ
Adv Anat Pathol; 2020 Sep; 27(5):331-353. PubMed ID: 32618586
[TBL] [Abstract][Full Text] [Related]
32. A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors.
Dessinioti C; Plaka M; Soura E; Mortaki D; Papaxoinis G; Gogas H; Stratigos AJ
Oncologist; 2019 Aug; 24(8):e755-e764. PubMed ID: 31073024
[TBL] [Abstract][Full Text] [Related]
33. [Not Available].
Basset-Seguin N
Ann Dermatol Venereol; 2018 Nov; 145 Suppl 5():VS36-VS41. PubMed ID: 30477683
[TBL] [Abstract][Full Text] [Related]
34. Vismodegib: A Review in Advanced Basal Cell Carcinoma.
Frampton JE; Basset-Séguin N
Drugs; 2018 Jul; 78(11):1145-1156. PubMed ID: 30030732
[TBL] [Abstract][Full Text] [Related]
35. Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia.
Mesti T; Sever M; Ocvirk J
Dermatology; 2023; 239(1):158-164. PubMed ID: 35896082
[TBL] [Abstract][Full Text] [Related]
36. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
[TBL] [Abstract][Full Text] [Related]
37. Targeting the Hedgehog Pathway for Locally Advanced and Metastatic Basal Cell Carcinoma.
Yin VT; Esmaeli B
Curr Pharm Des; 2017; 23(4):655-659. PubMed ID: 27928965
[TBL] [Abstract][Full Text] [Related]
38. Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.
Kudchadkar R; Lewis K; Gonzalez R
Semin Oncol; 2012 Apr; 39(2):139-44. PubMed ID: 22484185
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma.
Chang AL; Lewis KD; Arron ST; Migden MR; Solomon JA; Yoo S; Day BM; McKenna EF; Sekulic A
Oncotarget; 2016 Nov; 7(46):76118-76124. PubMed ID: 27764798
[TBL] [Abstract][Full Text] [Related]
40. A computational study of hedgehog signalling involved in basal cell carcinoma reveals the potential and limitation of combination therapy.
Buetti-Dinh A; Jensen R; Friedman R
BMC Cancer; 2018 May; 18(1):569. PubMed ID: 29776351
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]